Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, once again, is rather modest. We plan to catch up on some reading, promenade with our official mascot, and hang around with a short person or two. And what about you? This remains a fine time to forage for apples and pumpkins. You could shop for a Halloween costume (feel free to write us for suggestions). You might want to mail your ballot, but make sure the ballot box is kosher. Or you could look in on someone feeling isolated. Well, whatever you do, have a grand time. But be safe — wear a mask. Enjoy, and see you soon. …

A World Health Organization study of more than 11,000 people in 30 countries concluded that remdesivir appeared to have little or no effect on 28-day mortality or length of hospital stays among Covid-19 patients, The New York Times writes. The data have not yet been peer-reviewed or published in a scientific journal. Gilead Sciences (GILD), which sells the drug, disputed the conclusions, noting that a variety of drugs and drug combinations had been evaluated under a wide range of circumstances and that more rigorous studies had found a benefit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • The worldwide WHO study just sounds a little screwy to me to have complete trust in the outcome conclusions. Everyone is disregarding Remedsivir now on the internet. I find it strange that a well controlled study done in the US shows benefit and now a large WHO indicates no benefit. Remdesivir is a potent antiviral. I still regard the US study as meaningful. I have some doubts about the WHO study

Comments are closed.